Enasidenib for the treatment of relapsed or refractory...

Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation

Heiblig, Mael, Hachem-Khalife, Sabine, Willekens, Christophe, Micol, Jean-Baptiste, Paci, Angelo, Penard-Lacronique, Virginie, de Botton, Stéphane
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
5
Journal:
Expert Review of Precision Medicine and Drug Development
DOI:
10.1080/23808993.2020.1831909
Date:
November, 2020
File:
PDF, 745 KB
2020
Conversion to is in progress
Conversion to is failed